Skip to content

Joint Thoracic Oncology Research Unit of LYon: Lung cancerS DatabaSE (ULYSSE)

Prospective Longitudinal Cohort Associated to Blood Collection, Pathological Samples Collection, and Radiological and Pathological Imaging Collection

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05267041
Acronym
ULYSSE
Enrollment
4000
Registered
2022-03-04
Start date
2022-05-05
Completion date
2042-05-05
Last updated
2025-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Data collection, lung cancer

Brief summary

Prospective longitudinal cohort associated to blood collection, pathological samples collection, and radiological and pathological imaging collection.

Interventions

BIOLOGICALBlood sample

One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer

OTHERQuestionnaire

to collect data not reported in the patient's medical file, such as passive smoking, family history of cancer, and attempts to quit smoking.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

One questionnaire between diagnostic annoucement and first line treatement One 6 months later One before second line treatment One 6 months later after second line treatment Optionnal Veinous Blood Sample (28 mL) between the diagnostic annoucement and the first line of treatment

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient treated for a thoracic cancer in the Lyon University Hospital: non-small cell lung cancer, small cell lung cancer, mesothelioma… * Diagnosis can be done: * By cytology or pathologic assessment * Or by multidisciplinary team meeting decision: * Irradiation without morpho-metabolic sampling * Treatment without sampling based on non-invasive molecular data

Exclusion criteria

\- Refusal to participate For optional blood sampling : * \< 30 kg for blood collection * No blood sampling schedule for care

Design outcomes

Primary

MeasureTime frameDescription
Number of participants registered in the lung cancer database20 yearscohort open to recruitment during 10 years with 10 years of patients follow-up

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026